The clinical strategy aimed at reducing the burden or neutralizing the detrimental effects of the Senescence-Associated Secretory Phenotype (SASP), which consists of pro-inflammatory and tissue-damaging molecules secreted by senescent cells. Mitigating SASP is essential because these factors actively promote local tissue dysfunction and systemic inflammation, hindering hormonal efficacy. It addresses a core driver of aging pathology.
Origin
This term originates from cellular senescence research, where SASP was identified as a key mechanism by which aged cells negatively influence their microenvironment. Mitigation in the context of hormonal health is necessary because SASP factors directly contribute to the inflammatory microenvironment that causes hormone resistance. The goal is to clear this toxic cellular signaling.
Mechanism
Mitigation is often achieved through the targeted application of senolytic agents which selectively induce apoptosis in senescent cells, thereby eliminating the source of SASP secretion. Alternatively, interventions that improve autophagy or lysosomal function can reduce the intracellular accumulation of the signals that trigger SASP expression. Reducing this chronic inflammatory signaling directly improves tissue receptivity to anabolic hormones.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.